Bristol-Myers, Lexicon deal

Lexicon said it gained full rights to develop and commercialize LX9211 (BMS-986176), a compound that was discovered by the companies as part of a 2003 deal. Lexicon expects the oral small molecule neuropathic pain candidate to enter the clinic next year. Lexicon gained additional undisclosed small molecules acting on LX9211’s target (see BioCentury, Dec. 22, 2003)...